Company profile

ADC Therapeutics S.A.

Pipeline1 asset

loncastuximab tesirine-lpylZYNLONTA / CD19 / antibody-drug conjugate / Oncology
LOTIS-2 in 3L+ r/r DLBCLPhase 3/ConfirmatoryLOTIS-5 in r/r DLBCLPhase 3/ConfirmatoryLOTIS-7 in r/r B-NHLPhase 1b

Latest news5 items

May 4, 2026

ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates

May 1, 2026

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

Apr 27, 2026

ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026

Apr 1, 2026

ADC Therapeutics Announces New Employee Inducement Grant

Mar 10, 2026

ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

ADC Therapeutics S.A. • Endpoint Arena